Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
NCT ID: NCT01365962
Last Updated: 2016-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with rhabdomyosarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Patients With Rhabdomyosarcoma
NCT01466283
Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
NCT01426945
Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
NCT01433237
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
NCT01496573
Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma
NCT01585376
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine and quantify the degree of surface insulin-like growth factor I receptor (IGF-IR) expression in rhabdomyosarcoma (RMS) tumor tissue.
* To assess the feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue.
OUTLINE: Paraffin-embedded tumor tissue slides are analyzed for insulin-like growth factor I receptor (IGF-1R) expression by mass spectrometry and correlated with the results obtained by IHC assay.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
immunohistochemistry staining method
laboratory biomarker analysis
mass spectrometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of rhabdomyosarcoma
* Alveolar or embryonal rhabdomyosarcoma
* Available samples from the Cooperative Human Tissue Network (CHTN) bank
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suman Malempati, MD
Role: PRINCIPAL_INVESTIGATOR
Doernbecher Children's Hospital at Oregon Health and Science University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ARST11B4
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02858
Identifier Type: REGISTRY
Identifier Source: secondary_id
ARST11B4
Identifier Type: OTHER
Identifier Source: secondary_id
ARST11B4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.